Our Pipeline
|
TransCode Therapeutics has created a platform of therapeutic candidates with the objective of improving cancer patient outcomes.
Our lead therapeutic candidate, TTX-MC138, is focused on treating metastatic cancer, which has been shown to be responsible for the majority of all cancer deaths annually. Advancing a Pipeline of First-in-Class Therapeutic Candidates
Our other preclinical program includes a solid tumor program, TTX-siPDL1, an siRNA-based modulator of programmed death-ligand 1, or PD-L. TransCode also has two cancer agnostic programs, TTX-RIGA, an RNA- based agonist of the retinoic acid-inducible gene I, or RIG-I, targeting activation of innate immunity in the tumor microenvironment, and TTX-siMYC, a siRNA-based inhibitor of the c-myc oncogene.
Until now, targeting genetic markers that are the primary drivers of cancer onset, progression and recurrence have been locked behind the challenge of delivery – cytosolic delivery to engage these known targets. |
|